Connected Hospital Bed Manufacturer Security Risk Assessment Checklist
A connected hospital bed’s cybersecurity assessment should account for more than the bed’s onboard software. It should consider how network connections, service tools, cloud services, software suppliers, and hospital systems could affect bed functions, patient safety, and data.
Use this checklist to organize assessment work across design, development, deployment, maintenance, and end of support. It is a practical framework, not a substitute for product-specific risk management or regulatory review. FDA guidance describes the agency’s recommendations; it is generally nonbinding unless a specific statute or regulation applies. FDA’s current cybersecurity guidance for medical devices
What connected hospital bed assets and data should manufacturers inventory?
Start with a system boundary that includes the bed and the connected services and infrastructure it depends on. Record each asset’s purpose, owner, software or firmware version, interfaces, deployment environment, and support status.
- Bed hardware and electronics: Identify control units, motor controllers, displays, sensors, communication modules, and service or debug ports. Include optional components such as bed-exit detection, scales, or nurse-call interfaces only where the product supports them.
- Software and firmware: Inventory embedded code, operating systems, libraries, third-party components, applications, and configuration files. Maintain a software bill of materials (SBOM) that includes commercial, open-source, and off-the-shelf components where applicable.
- Connections and supporting systems: Map Wi-Fi, Bluetooth, wired network, USB, or other interfaces actually present, along with mobile apps, gateways, hospital systems, update servers, cloud services, and manufacturer service tools.
- Data and commands: Identify what the bed collects, stores, transmits, or receives—for example, device identifiers, configuration, status, alarm events, or patient-associated information. Document where each data type goes and which system can issue commands or change settings.
- People and credentials: List user roles, service personnel, administrators, supplier access, authentication methods, certificates, keys, and other secrets. Note how accounts and credentials are provisioned, changed, and revoked.
- Lifecycle and supply chain: Record component suppliers, manufacturing and provisioning steps, deployment assumptions, maintenance dependencies, expected support periods, and end-of-life processes.
Keep the inventory current as configurations change. For cyber devices within the scope of FD&C Act section 524B, FDA identifies a software bill of materials as one of the submission requirements; the applicable obligations depend on the device and submission. FDA’s cybersecurity FAQs
How should manufacturers assess threats and vulnerabilities across the bed lifecycle?
Assess plausible ways a weakness could be reached, exploited, and translated into a clinical or operational consequence. Include intended use and reasonably foreseeable misuse, such as unauthorized access through a service interface, compromised credentials, unsafe configuration changes, or disruption of a connected service.
- Trace attack paths: Follow data, code, and commands across interfaces, applications, gateways, facility networks, and update infrastructure. Identify trust boundaries and assumptions about systems outside the manufacturer’s control.
- Consider bed-specific consequences: Evaluate whether an attack could affect powered movement, positioning, alarms, bed-exit functions, settings, or the availability of the bed. Assess data confidentiality and integrity as well as device availability.
- Cover each lifecycle stage: Consider design and development, component sourcing, manufacturing, shipment, installation, clinical use, servicing, software updates, transfer, and decommissioning.
- Include varied threat sources: Assess malicious actors, compromised suppliers or components, unauthorized users, accidental changes, and physical access. Tailor scenarios to the bed’s actual interfaces and operating environment.
- Link security risks to safety risks: Evaluate how a cybersecurity event could contribute to a hazard or harm, and record the assumptions, existing controls, and residual risk.
Use ISO 14971 as a risk-management reference for medical devices, and consider how IEC 62304 supports the software lifecycle processes for embedded or integral medical-device software. IEC 81001-5-1 addresses security activities in the health-software product lifecycle. These standards can inform a manufacturer’s process; referencing a standard alone does not establish that a particular product is secure or meets every applicable requirement.
What cybersecurity controls should the checklist evaluate?
Evaluate controls against the threats and risks identified for the specific bed system. For each control, document where it is implemented, what risk it addresses, how it is tested, and what happens if it fails.
- Authentication and authorization: Check that access is limited to appropriate users and functions, default credentials are addressed, privileged access is restricted, and service access is controlled.
- Secure communications and data protection: Assess whether sensitive data and commands are protected in transit and at rest where appropriate. Review key and certificate management, including provisioning, rotation, revocation, and protection from exposure.
- Software and configuration integrity: Verify that update packages and executable code are authenticated, unauthorized changes are detected or prevented, and configurations are protected against unintended modification.
- Secure updates and recovery: Confirm that update mechanisms are controlled and that a failed or interrupted update has a defined recovery path. Assess how patches can be deployed without creating unacceptable safety or availability risks.
- Hardening and interface controls: Review enabled services, unused ports, debug features, removable media, physical access, and secure configuration options. Confirm that unnecessary functionality is disabled or appropriately protected.
- Logging, detection, and resilience: Determine whether relevant security events can be detected and investigated, and whether the bed can recover from disruption. Ensure logging and recovery mechanisms do not interfere with safe clinical operation.
- Supplier and development practices: Review how third-party components are selected, tracked, tested, and updated. A secure product development framework can help organize these practices; NIST’s Secure Software Development Framework provides recommended practices that can be integrated into a software development lifecycle.
FDA’s current guidance discusses security risk management, architecture, testing, controls, and lifecycle considerations. Treat its recommendations as guidance, and separately identify any statutory or regulatory requirements that apply to the specific device and submission. FDA cybersecurity guidance for medical devices
Ready to assess your HIPAA security risks?
Join thousands of organizations that use Accountable to identify and fix their security gaps.
Take the Free Risk AssessmentHow can manufacturers verify wireless, network, and software security?
Test the interfaces and configurations included in the product’s defined scope, not just the bed in isolation. Document the test setup, firmware and software versions, network assumptions, tools, results, and limitations so that findings can be reproduced and assessed.
- Wireless interfaces: Where wireless features are present, assess pairing and authentication, access control, encryption, configuration, and behavior when connections are lost or interrupted. Test whether unauthorized devices can connect or send commands.
- Network paths: Verify that documented protocols, ports, and services match the product’s actual behavior. Test expected network configurations and assess how the bed responds to malformed, unexpected, or excessive traffic.
- Software and firmware: Use appropriate static and dynamic analysis, dependency and vulnerability scanning, and penetration testing. Evaluate update validation, rollback or recovery behavior, and whether test findings are resolved or formally assessed.
- Safety and security together: Confirm that cybersecurity controls and test scenarios do not create unacceptable effects on intended bed functions. Test relevant loss-of-connectivity, recovery, and degraded-operation scenarios.
- System-level assumptions: Record which protections depend on a hospital network, gateway, mobile application, cloud service, or service workstation. Test interfaces between these elements and make assumptions clear to users and deployers.
Use architecture diagrams and explanatory text to show system elements, interfaces, communication paths, and the controls protecting them. FDA’s guidance recommends documentation scaled to the device’s cybersecurity risks and attack surfaces. FDA’s current premarket cybersecurity guidance
What evidence should support risk ratings and remediation decisions?
A risk rating should be traceable to evidence, not just a score or an undocumented judgment. Record the method used, its assumptions, the evidence considered, and how the rating connects to possible patient or operational consequences.
- Assessment records: Keep the system boundary, asset inventory, data-flow and architecture diagrams, threat model, hazard analysis, and traceability between identified risks and controls.
- Technical evidence: Retain test plans and results, vulnerability scans, penetration-test findings, software composition records, SBOM versions, supplier information, and relevant configuration baselines.
- Risk rationale: Document exploitability, potential impact, exposure, existing mitigations, affected versions, uncertainty, and residual risk. Explain why a finding is accepted, mitigated, deferred, or escalated.
- Remediation evidence: Link each corrective action to its owner, priority, target date, validation results, affected product versions, and any customer or user communications.
- Approval and change history: Record review decisions, responsible approvers, changes to assumptions, and reassessments after significant design, software, supplier, or threat changes.
FDA’s guidance describes cybersecurity risk-management and documentation recommendations for medical devices, while ISO 14971 provides a framework for medical-device risk management. Apply the organization’s defined criteria consistently and explain how security findings were assessed in the context of bed safety and intended use. FDA guidance · ISO 14971
How should manufacturers manage post-market monitoring and incident response?
Maintain a process to receive, assess, prioritize, and address vulnerability information after release. For cyber devices subject to section 524B, the statute includes a plan to monitor, identify, and address post-market vulnerabilities and exploits, including coordinated vulnerability disclosure, as well as processes for cybersecurity and post-market updates and patches. FDA’s cybersecurity FAQs
- Monitor relevant information: Review vulnerability disclosures, component and supplier notices, security research, incident reports, and product support channels. Match findings to affected components, versions, and configurations.
- Operate a vulnerability disclosure program: Provide a clear way to report security issues, acknowledge and triage reports, protect sensitive details during investigation, and coordinate communication with reporters and affected parties.
- Assess patient and operational risk: Reproduce or validate the issue where feasible, identify affected beds and dependencies, evaluate potential safety impact, and determine whether interim controls or a product update are appropriate.
- Plan and validate remediation: Define containment, corrective action, testing, deployment, and follow-up. Consider whether changes affect safety, performance, labeling, or regulatory submissions.
- Communicate and escalate: Inform affected customers and users about relevant risks, mitigations, and update availability. Assess whether regulatory reporting or other notifications are required for the specific event.
- Learn from incidents: Update the threat model, risk assessment, secure development practices, supplier expectations, and response procedures based on findings and lessons learned.
FDA’s post-market guidance recommends addressing cybersecurity throughout the product lifecycle, including design, development, production, distribution, deployment, and maintenance. FDA’s post-market cybersecurity guidance Taken together, a strong assessment connects a maintained asset inventory to patient-centered risk analysis, tested controls, documented decisions, and ongoing vulnerability response.
FAQs.
What cybersecurity risks are specific to connected hospital beds?
Risks depend on a bed’s design and connectivity. Relevant scenarios to assess include unauthorized changes to settings or commands, loss or disruption of connected functions, interference with alarms or bed-exit features, compromise of service access, and exposure or alteration of device or patient-associated data. Evaluate each scenario against the actual bed functions and its clinical environment.
How should manufacturers assess vulnerabilities in bed firmware and wireless interfaces?
Inventory firmware, software dependencies, versions, and wireless interfaces, then test the product’s actual configurations and data paths. Use appropriate code and dependency analysis, vulnerability scanning, and penetration testing; assess whether unauthorized access or updates are possible; and evaluate how failures could affect safe operation. Record findings, affected versions, mitigations, and retest results.
What documentation should support a connected bed security risk assessment?
Keep an asset inventory, system and data-flow diagrams, threat model, risk and hazard analysis, control-to-risk traceability, SBOM, security test results, remediation records, and documented residual-risk decisions. Include versions, assumptions, approvals, and the rationale for risk ratings so that assessments can be reviewed and updated.
How should manufacturers handle newly identified vulnerabilities after product release?
Receive and triage the report, determine affected products and versions, validate the vulnerability, and assess cybersecurity and patient-safety impact. Apply interim mitigations where appropriate, develop and validate a corrective action or patch, communicate relevant information to affected users, and assess applicable regulatory reporting obligations. Update the risk assessment and monitoring plan with the outcome.
Table of Contents
- What connected hospital bed assets and data should manufacturers inventory?
- How should manufacturers assess threats and vulnerabilities across the bed lifecycle?
- What cybersecurity controls should the checklist evaluate?
- How can manufacturers verify wireless, network, and software security?
- What evidence should support risk ratings and remediation decisions?
- How should manufacturers manage post-market monitoring and incident response?
-
FAQs.
- What cybersecurity risks are specific to connected hospital beds?
- How should manufacturers assess vulnerabilities in bed firmware and wireless interfaces?
- What documentation should support a connected bed security risk assessment?
- How should manufacturers handle newly identified vulnerabilities after product release?
Ready to assess your HIPAA security risks?
Join thousands of organizations that use Accountable to identify and fix their security gaps.
Take the Free Risk Assessment